FDA Backs Telaprevir for Having High Hepatitis C Cure Rate
Vertex’s hepatitis C drug aces review
Telaprevir cures more people more quickly than current options
April 27, 2011 | By Robert Weisman, Globe Staff
A drug developed by Vertex Pharmaceuticals Inc. cures more patients with the hepatitis C virus in less time than existing therapies, according to a briefing document filed yesterday by Food and Drug Administration staffers who reviewed the company’s application for approval.
Continue reading this entire article:
Hep C Drug Boceprevir is Faster and Better
May 23 Could Bring Approval for Vertex's Hep C Drug